Epigenome-wide association study of COVID-19 severity with respiratory failure


Por: de Moura, MC, Davalos, V, Planas-Serra, L, Alvarez-Errico, D, Arribas, C, Ruiz, M, Aguilera-Albesa, S, Troya, J, Valencia-Ramos, J, Velez-Santamaria, V, Rodriguez-Palmero, A, Villar-Garcia, J, Horcajada, JP, Albu, S, Casasnovas, C, Rull, A, Reverte, L, Dietl, B, Dalmau, D, Arranz, MJ, Llucia-Carol, L, Planas, AM, Perez-Tur, J, Fernandez-Cadenas, I, Villares, P, Tenorio, J, Colobran, R, Martin-Nalda, A, Soler-Palacin, P, Vidal, F, Pujol, A, Esteller, M

Publicada: 1 abr 2021 Ahead of Print: 1 abr 2021
Resumen:
Background: Patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the coronavirus disease 2019 (COVID-19), exhibit a wide spectrum of disease behaviour. Since DNA methylation has been implicated in the regulation of viral infections and the immune system, we performed an epigenome-wide association study (EWAS) to identify candidate loci regulated by this epigenetic mark that could be involved in the onset of COVID-19 in patients without comorbidities. Methods: Peripheral blood samples were obtained from 407 confirmed COVID-19 patients <= 61 years of age and without comorbidities, 194 (47.7%) of whom had mild symptomatology that did not involve hospitaliza-tion and 213 (52.3%) had a severe clinical course that required respiratory support. The set of cases was divided into discovery (n = 207) and validation (n = 200) cohorts, balanced for age and sex of individuals. We analysed the DNA methylation status of 850,000 CpG sites in these patients. Findings: The DNA methylation status of 44 CpG sites was associated with the clinical severity of COVID-19. Of these loci, 23 (52.3%) were located in 20 annotated coding genes. These genes, such as the inflammasome component Absent in Melanoma 2 (AIM2) and the Major Histocompatibility Complex, class I C (HLA-C) candi-dates, were mainly involved in the response of interferon to viral infection. We used the EWAS-identified sites to establish a DNA methylation signature (EPICOVID) that is associated with the severity of the disease. Interpretation: We identified DNA methylation sites as epigenetic susceptibility loci for respiratory failure in COVID-19 patients. These candidate biomarkers, combined with other clinical, cellular and genetic factors, could be useful in the clinical stratification and management of patients infected with the SARS-CoV-2. (C) 2021 The Authors. Published by Elsevier B.V.

Filiaciones:
de Moura, MC:
 Josep Carreras Leukaemia Res Inst IJC, Barcelona 08916, Catalonia, Spain

Davalos, V:
 Josep Carreras Leukaemia Res Inst IJC, Barcelona 08916, Catalonia, Spain

Planas-Serra, L:
 Bellvitge Biomed Res Inst IDIBELL, Neurometab Dis Lab, Barcelona 08908, Catalonia, Spain

Alvarez-Errico, D:
 Josep Carreras Leukaemia Res Inst IJC, Barcelona 08916, Catalonia, Spain

Arribas, C:
 Josep Carreras Leukaemia Res Inst IJC, Barcelona 08916, Catalonia, Spain

Ruiz, M:
 Bellvitge Biomed Res Inst IDIBELL, Neurometab Dis Lab, Barcelona 08908, Catalonia, Spain

Aguilera-Albesa, S:
 Navarra Hlth Serv Hosp, Pamplona, Spain

Troya, J:
 Infanta Leonor Univ Hosp, Madrid, Spain

Valencia-Ramos, J:
 Univ Hosp Burgos, Burgos, Spain

Velez-Santamaria, V:
 Bellvitge Biomed Res Inst IDIBELL, Neurometab Dis Lab, Barcelona 08908, Catalonia, Spain

 Bellvitge Univ Hosp, Barcelona, Catalonia, Spain

Rodriguez-Palmero, A:
 Bellvitge Biomed Res Inst IDIBELL, Neurometab Dis Lab, Barcelona 08908, Catalonia, Spain

 Univ Hosp Germans Trias & Pujol, Barcelona, Catalonia, Spain

Villar-Garcia, J:
 Hosp del Mar IMIM Biomed Res Inst, Barcelona, Catalonia, Spain

Horcajada, JP:
 Hosp del Mar IMIM Biomed Res Inst, Barcelona, Catalonia, Spain

Albu, S:
 Inst Guttmann Fdn, Barcelona, Catalonia, Spain

Casasnovas, C:
 Bellvitge Biomed Res Inst IDIBELL, Neurometab Dis Lab, Barcelona 08908, Catalonia, Spain

 Bellvitge Univ Hosp, Barcelona, Catalonia, Spain

Rull, A:
 Univ Rovira & Virgili, Hosp Univ Tarragona Joan XXIII, IISPV, Tarragona, Catalonia, Spain

Reverte, L:
 Univ Rovira & Virgili, Hosp Univ Tarragona Joan XXIII, IISPV, Tarragona, Catalonia, Spain

Dietl, B:
 Univ Barcelona, Serv Malalties Infeccioses Hosp Univ MutuaTerrass, Barcelona, Catalonia, Spain

Dalmau, D:
 Univ Barcelona, HIV AIDS Unit Hosp Univ MutuaTerrassa, MutuaTerrassa Res & Innovat Fdn, Barcelona, Catalonia, Spain

Arranz, MJ:
 Fundacio Docencia & Recerca Mutua Terrassa, Barcelona, Catalonia, Spain

 Hosp Univ Mutua Terrassa, Barcelona, Catalonia, Spain

Llucia-Carol, L:
 St Pau Hosp, St Pau Inst Res, Stroke Pharmacogen & Genet Grp, Barcelona, Catalonia, Spain

Planas, AM:
 Inst Invest Biomed August Pi & Sunyer IDIBAPS, Inst Invest Biomed Barcelona IIBB, Dept Brain Ischem & Neurodegenerat, CSIC,Area Neurosci, Barcelona, Catalonia, Spain

Perez-Tur, J:
 IIS La Fe, Inst Biomed Valencia CSIC, Unitat Mixta Neurol & Genet, CIBERNED, Vallencia, Spain

Fernandez-Cadenas, I:
 St Pau Hosp, St Pau Inst Res, Stroke Pharmacogen & Genet Grp, Barcelona, Catalonia, Spain

Villares, P:
 Hosp HM Sanchinarro, HM Hosp, Internal Med Dept, Madrid, Spain

Tenorio, J:
 Hosp Univ La Paz, INGEMM Inst Genet Med & Mol, Madrid, Spain

 ISCIII, Ctr Biomed Res Rare Dis CIBERER, Madrid, Spain

Colobran, R:
 UAB, Hosp Univ Vall dHebron, Immunol Div, Vall dHebron Res Inst,Genet Dept, Vall dHebron Barcelona Hosp Campus, Barcelona, Catalonia, Spain

Martin-Nalda, A:
 Hosp Univ Vall dHebron, Pediat Infect Dis & Immunodeficiencies Unit, Vall dHebron Barcelona Hosp Campus, Barcelona, Catalonia, Spain

Soler-Palacin, P:
 Hosp Univ Vall dHebron, Pediat Infect Dis & Immunodeficiencies Unit, Vall dHebron Barcelona Hosp Campus, Barcelona, Catalonia, Spain

Vidal, F:
 Univ Rovira & Virgili, Hosp Univ Tarragona Joan XXIII, IISPV, Tarragona, Catalonia, Spain

Pujol, A:
 Bellvitge Biomed Res Inst IDIBELL, Neurometab Dis Lab, Barcelona 08908, Catalonia, Spain

 ISCIII, Ctr Biomed Res Rare Dis CIBERER, Madrid, Spain

 Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Catalonia, Spain

Esteller, M:
 Josep Carreras Leukaemia Res Inst IJC, Barcelona 08916, Catalonia, Spain

 Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain

 Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Catalonia, Spain

 Univ Barcelona UB, Sch Med & Hlth Sci, Physiol Sci Dept, Barcelona, Catalonia, Spain
ISSN: 23523964





EBioMedicine
Editorial
ELSEVIER, RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS, Reino Unido
Tipo de documento: Article
Volumen: 66 Número:
Páginas:
WOS Id: 000647713400012
ID de PubMed: 33867313
imagen Green Published, gold

MÉTRICAS